Loading
Roginolisib is an oral pi3k inhibitor from iOnctura, in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer.
Roginolisib is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by iOnctura, in non-small-cell lung cancer, small-cell lung cancer. A phosphoinositide 3-kinase inhibitor: the name stem -lisib marks a small molecule that blocks PI3K signalling. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
A phosphoinositide 3-kinase inhibitor: the name stem -lisib marks a small molecule that blocks PI3K signalling.
1.Roginolisib slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Roginolisib" OR ABSTRACT:"Roginolisib" OR TITLE:"IOA-244" OR ABSTRACT:"IOA-244") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Roginolisib, not a curated reading list.
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tags pipeline, registry-only.
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tags pipeline, registry-only.
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tags pipeline, registry-only.
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tags pipeline, registry-only.
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tags pipeline, registry-only.
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tags pipeline, registry-only.
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tags pipeline, registry-only.
Shares Non-small-cell lung cancer and the tags pipeline, registry-only.